Tower Research Capital (TRC)’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-2,083
Closed -$7K 7024
2022
Q2
$7K Sell
2,083
-1,486
-42% -$5.79K ﹤0.01% 4884
2022
Q1
$15K Sell
3,569
-5,183
-59% -$22.6K ﹤0.01% 3862
2021
Q4
$41K Buy
8,752
+3,420
+64% +$14.3K ﹤0.01% 2934
2021
Q3
$21K Sell
5,332
-1,244
-19% -$4.94K ﹤0.01% 3694
2021
Q2
$28K Sell
6,576
-1,436
-18% -$6.15K ﹤0.01% 3588
2021
Q1
$34K Buy
8,012
+1,650
+26% +$9.09K ﹤0.01% 3475
2020
Q4
$24K Sell
6,362
-15,318
-71% -$65.5K ﹤0.01% 3766
2020
Q3
$88K Sell
21,680
-3,331
-13% -$13.8K ﹤0.01% 3246
2020
Q2
$106K Buy
+25,011
New +$152K ﹤0.01% 2404
2020
Q1
Sell
-8,399
Closed -$33K 4508
2019
Q4
$33K Buy
8,399
+8,343
+14,898% +$49.3K ﹤0.01% 1615
2019
Q3
$0 Sell
56
-10
-15% -$94 ﹤0.01% 4902
2019
Q2
$1K Sell
66
-4,508
-99% -$34K ﹤0.01% 3582
2019
Q1
$30K Buy
+4,574
New +$29.8K ﹤0.01% 2061
2018
Q4
Sell
-4,241
Closed -$85K 4836
2018
Q3
$85K Buy
+4,241
New +$111K 0.01% 1452
2018
Q2
Sell
-12,833
Closed -$382K 4494
2018
Q1
$382K Buy
+12,833
New +$414K 0.03% 600
2017
Q4
Sell
-1,988
Closed -$69K 4537
2017
Q3
$69K Buy
1,988
+1,594
+405% +$51.3K 0.01% 1702
2017
Q2
$12K Sell
394
-527
-57% -$15.1K ﹤0.01% 1550
2017
Q1
$27K Buy
921
+51
+6% +$1.3K ﹤0.01% 1112
2016
Q4
$15K Buy
870
+159
+22% +$3.05K ﹤0.01% 2408
2016
Q3
$17K Sell
711
-1,595
-69% -$30.1K ﹤0.01% 1738
2016
Q2
$37K Buy
+2,306
New +$41.4K ﹤0.01% 1782
2016
Q1
Sell
-230
Closed -$6K 5855
2015
Q4
$6K Sell
230
-554
-71% -$15.1K ﹤0.01% 2917
2015
Q3
$22K Sell
784
-118
-13% -$3.72K ﹤0.01% 1676
2015
Q2
$22K Buy
902
+878
+3,658% +$18.1K ﹤0.01% 2045
2015
Q1
$0 Sell
24
-6
-20% -$122 ﹤0.01% 5645
2014
Q4
$1K Sell
30
-248
-89% -$2.94K ﹤0.01% 3927
2014
Q3
$3K Buy
+278
New +$2.77K ﹤0.01% 3749
2014
Q2
Sell
-542
Closed -$6K 5489
2014
Q1
$6K Buy
+542
New +$5.32K ﹤0.01% 3215

Tower Research Capital (TRC)'s LJPC Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 2,083 shares — an estimated $7K sold.

Tower Research Capital (TRC) first reported a position in LJPC in Q1 2014 and held it in 28 quarters. The position peaked at $382K in Q1 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.

  • Tower Research Capital (TRC) reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,083 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $7K.
  • Tower Research Capital (TRC) first reported a position in La Jolla Pharmaceutical Company in Q1 2014 and held it in 28 quarters.
  • Tower Research Capital (TRC)'s La Jolla Pharmaceutical Company position peaked at $382K in Q1 2018.
  • 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.